Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX4DUR)

Drug Name

2-(3-bromobenzoylamino)-4-chlorobenzoic acid Drug Info

Synonyms

827325-60-0; 2-[(3-bromobenzoyl)amino]-4-chlorobenzoic acid; CHEMBL225612; 2-(3-Bromobenzamido)-4-chlorobenzoic acid; Benzoic acid, 2-[(3-bromobenzoyl)amino]-4-chloro-; 2-(3-bromobenzoylamino)-4-chlorobenzoic acid; AC1N8QX1; SCHEMBL14075271; CTK3D6918; KS-00003MRF; DTXSID50401927; MolPort-002-885-931; ZINC4104976; ZX-AN021268; ALBB-022752; BDBM50158557; AKOS005107642; MCULE-7998531013; MS-0095; R4909; SR-01000309735; SR-01000309735-1; 2-[(3-bromobenzoyl)amino]-4-chlorobenzenecarboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 4323128
CAS Number: CAS 827325-60-0
TTD Drug ID: DMX4DUR

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glutamate receptor ionotropic kainate 1 (GRIK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[2]
LY293558	DM4N6EK	Pain	MG30-MG3Z	Phase 2	[3]
NS 1209	DM9EFH0	Epilepsy	8A60-8A68	Phase 2	[4]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[5]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[5]
[3H]kainate	DMMK7XU	Discovery agent	N.A.	Investigative	[6]
[3H]quisqualate	DMDQBTX	Discovery agent	N.A.	Investigative	[7]
SYM2081	DM30WDL	Discovery agent	N.A.	Investigative	[6]
DNQX	DMQXPA5	Discovery agent	N.A.	Investigative	[8]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor ionotropic kainate 1 (GRIK1)	TT0MYE2	GRIK1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Bioisosteric modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. J Med Chem. 2004 Dec 30;47(27):6948-57.
2	Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43.
3	Pharmacogenetics of new analgesics. Br J Pharmacol. 2011 Jun;163(3):447-60.
4	The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9.
5	4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
7	Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103.
8	Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.